New TOGETHER-PsO data from Lilly: by week 36 the combo changed 482 proteins and 467 genes, against 140 and 16 with ixekizumab on its own.
Recap by typeshit. Full story at HCPLive.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Pairing eloralintide with tirzepatide beat tirzepatide alone at 48 weeks, at 23.3% versus 14.8% weight loss. Up to about a quarter of people on the combo quit because of side effects.
Dr Rosenstein breaks down the Ozempic face term and says weight loss can help some patients, though not everyone needs the same approach.
Loading…